5 results about "Microarray profiling" patented technology

The application provides application of maternal blood exosome miR-1909-3p as a biomarker in preparation of a product for diagnosing or assisting in diagnosing fetal congenital heart disease, and belongs to the technical field of in vitro diagnosis. The application uses miRNA microarray analysis to analyze the expression characteristics of serum exosome microRNAs affected by CHD compared with matched healthy controls. In the early and late pregnancy of TOF fetus, miR-1909-3p is significantly overexpressed in the maternal circulation, indicating that miR-1909-3p is a potential biomarker for fetal congenital heart disease. Through ROC curve analysis of the verification set, it is found that the area under the curve is 0.953, P<0.001, the sensitivity is 95%, and the specificity is 95%, indicating that miR-1909-3p can be used as a potential non-invasive biomarker for prenatal CHD screening.

The present invention provides a gender-neutral, non-invasive diagnostic method for detecting urological cancers, including prostate, bladder, kidney, renal pelvis, and testis cancers, using urine-based microRNA (miRNA) biomarkers. The method comprises obtaining a self-collected urine sample, extracting miRNA, and quantifying biomarker expression levels using, e.g., reverse transcription quantitative PCR (RT-qPCR), next-generation sequencing (NGS), or microarray analysis. A panel of miRNAs, e.g., hsa-let-7b-5p, hsa-miR-26b-5p, hsa-miR-145-5p, hsa-miR-4253p, hsa-miR-195-5p, hsa-miR-203a-3p, hsa-miR-30c-5p, and hsa-miR-30a-3p, enables sensitive and specific discrimination between cancer and non-cancer patients. The invention is capable of high diagnostic performance and accuracy. The assay may be highly reproducible. This present invention provides a cost-effective, non-invasive, inclusive platform applicable across cisgender, transgender, and non-binary populations, facilitating early cancer detection and improved healthcare accessibility.

The present invention provides a gender-neutral, non-invasive diagnostic method for detecting urological cancers, including prostate, bladder, kidney, renal pelvis, and testis cancers, using urine-based microRNA (miRNA) biomarkers. The method comprises obtaining a self-collected urine sample, extracting miRNA, and quantifying biomarker expression levels using, e.g., reverse transcription quantitative PCR (RT-qPCR), next-generation sequencing (NGS), or microarray analysis. A panel of miRNAs, e.g., hsa-let-7b-5p, hsa-miR-26b-5p, hsa-miR-145-5p, hsa-miR-4253p, hsa-miR-195-5p, hsa-miR-203a-3p, hsa-miR-30c-5p, and hsa-miR-30a-3p, enables sensitive and specific discrimination between cancer and non-cancer patients. The invention is capable of high diagnostic performance and accuracy. The assay may be highly reproducible. This present invention provides a cost-effective, non-invasive, inclusive platform applicable across cisgender, transgender, and non-binary populations, facilitating early cancer detection and improved healthcare accessibility.

The invention discloses a biomarker for diagnosing ankylosing spondylitis. The biomarker is G6PD in a human peripheral blood mononuclear cell. The invention utilizes microarray analysis to detect differentially expressed mRNA in peripheral blood mononuclear cells, and confirms that these candidate mRNAs are indeed different and can be used as potential biomarkers for diagnosis of ankylosing spondylitis. The result shows that the expression change of the G6PD in the peripheral blood mononuclear cells of an ankylosing spondylitis patient can be used as a marker for diagnosing the ankylosing spondylitis, which is beneficial to exploring the pathogenesis of the disease, provides a new direction for the diagnosis of the ankylosing spondylitis and has a wide clinical application prospect.

The invention discloses a biomarker for evaluating the activity of ankylosing spondylitis. The biomarker is CYBB in human peripheral blood mononuclear cells. The invention utilizes microarray analysis to detect differentially expressed mRNAs in peripheral blood mononuclear cells, and confirms that these candidate mRNAs are indeed different and can be used as potential biomarkers for diagnosis of ankylosing spondylitis. The result shows that the expression quantity change of the CYBB in the peripheral blood mononuclear cells of the ankylosing spondylitis patient is positively correlated with the disease activity of the AS patient, and the CYBB plays a marker role in the diagnosis, activity evaluation and curative effect evaluation of the AS patient.